tbuckley/cabot-search huggingface dataset:
Two for one influenza immunisation: mothers and infants
Authors: R J P José
Journal: Thorax (2009)

The World Health Organization recommends immunisation of pregnant women with inactivated influenza vaccine to reduce the risks associated with influenza infection in mothers and infants; however, the vaccine is not licensed for infants under 6 months of age.

This prospective blinded randomised controlled trial assessed the safety and immunogenicity of pneumococcal vaccine (control group) and the clinical efficacy of …
Activity, Efficacy and Safety of Nab-Paclitaxel (Nab-P) and Gemcitabine (G) in Advanced Pancreatic Cancer (Apdac) Elderly Patients
Authors: G. Giordano, D. Melisi, M. Milella, A. Zaniboni, E. Vasile, V. Zagonel, E. Giommoni, L. Maiorino, M. Santoni, V. Vaccaro, P. Bertocchi, F. Bergamo, G. Musettini, E. Lucchini, S. Cascinu, A. Febbraro
Journal: Annals of Oncology (2014)
Differential Effects of Sera from Normotensive and Hypertensive Pregnant Women on Ca2+ Metabolism in Normal Vasular Smooth Muscle Cells
Authors: JACOB GREEN, SUHEIR ASSADY, FARID NAKHOUL, TOVA BICK, PETER JAKOBI, ZAID ABASSI
Journal: Journal of the American Society of Nephrology (2000)

Abstract. The clinical features of preeclampsia have been traditionally ascribed to a generalized vascular endothelial cell dysfunction. The present study investigates the effect of sera from preeclamptic women and normal pregnancy on the metabolism of intracellular Ca 2+ concentration ([Ca 2+ ] i ) in normal cultured vascular smooth muscle cells (VSMC). Sera were obtained from normotensive pregnant women (NTP) ( n = 17), preeclamptic women (PE) ( n = 15), pregnant women with chronic (essential) hypertension (pregnant EHT) ( n = 8), non-pregnant women with essential hypertension (non-pregnant EHT) ( n = 12), and age-matched non-pregnant normotensive women (NNP) ( n = 18). Serum (10%) was applied to both primary cultures of rat aortic smooth muscle cells and to the A-10 vascular muscle cell line. Levels of [Ca 2+ ] i were determined fluorometrically. After a 4-h incubation with serum, basal [Ca 2+ ] i was not significantly altered. However, compared with normal pregnant sera, PE sera markedly reduced hormonally induced Ca 2+ transients. Thus, following acute stimulation of rat VSMC (primary cultures) with 10 -8 M angiotensin II, peak [Ca 2+ ] i responses (% increment over baseline) were 443 ± 22, 184 ± 18, 259 ± 12, 274 ± 23, and 255 ± 15% in NTP, PE, pregnant EHT, non-pregnant EHT, and NNP, respectively ( P &lt;0.01 PE versus NTP, P &lt;0.05 PE versus NNP and pregnant and non-pregnant EHT). These effects of sera on [Ca 2+ ] i were qualitatively reproduced in platelets obtained from healthy volunteers. Also, depolarization-activated Ca 2+ influx in VSMC was affected by the different sera groups in a manner similar to that seen with hormonally induced [Ca 2+ ] i responses. The altered [Ca 2+ ] i changes by PE sera disappeared 5 wk after delivery. The effect of the different sera groups on hormonally triggered Ca 2+ transients in normal VSMC, as well as the normalization of [Ca 2+ ] i responses after delivery, suggest the presence of a circulating serum factor in PE. Inasmuch as [Ca 2+ ] i is the major determinant of VSMC tone, it is possible that consequent to the attenuation of [Ca 2+ ] i responses, this putative circulating factor counterbalances the intense vasoconstriction in PE.
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Authors: Michael Andreeff, Kevin R. Kelly, Karen Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David Bowen, Giovanni Martinelli, Mark W. Drummond, Paresh Vyas, Mark Kirschbaum, Swaminathan Padmanabhan Iyer, Vivian Ruvolo, Graciela M. Nogueras González, Xuelin Huang, Gong Chen, Bradford Graves, Steven Blotner, Peter Bridge, Lori Jukofsky, Steve Middleton, Monica Reckner, Ruediger Rueger, Jianguo Zhi, Gwen Nichols, Kensuke Kojima
Journal: Clinical Cancer Research (2015)

RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted.Primary study objectives included determination of the dose and safety profile of RG7112. Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL). Some Stratum A patients were treated at the MTD to assess clinical activity.RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B). All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported. Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure. Antileukemia activity was observed in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response. Exploratory analysis revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients. Two patients with TP53 mutations exhibited clinical activity. p53 target genes were induced only in TP53 wild-type leukemic cells. Baseline expression levels of MDM2 correlated positively with clinical response.RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies.
Hepatitis A outbreak in an Orthodox Jewish community in London, July 2010
Authors: M Edelstein, D Turbitt, K Balogun, J Figueroa, G Nixon
Journal: Eurosurveillance (2010)

A cluster of hepatitis A cases in the Orthodox Jewish community in London, United Kingdom in July 2010 has triggered extensive contact tracing and vaccination. Two primary cases imported from a common source in Israel and three secondary cases have resulted in immunisation of over 900 contacts to date. Rapid response by local public health, primary care services and a dedicated community health team, and active hepatitis A vaccination rather than immunoglobulin treatment were used to avert a larger outbreak.
Overall Survival and Biomarker Results from a Phase 2 Study of Mek1/2 Inhibitor Binimetinib (Mek162) in Patients with Advanced Nras-Mutant Melanoma
Authors: C. van Herpen, S.S. Agarwala, A. Hauschild, R. Dummer, C. Berking, J.T. Beck, D. Schadendorf, G. Gibney, R. Jansen, P. Queirolo, P.A. Ascierto, C. Blank, H. Nauwelaerts, F. Niazi, R.R. Pal, A. Reddy, V. Antona, A. Zubel, M.C. Heinrich
Journal: Annals of Oncology (2014)
Cherchez la Femme: Reproductive CRISPR and Women's Choices
Authors: Megan Allyse, Marsha Michie, Jessica Mozersky, Rayna Rapp
Journal: The American Journal of Bioethics (2015)

This AJOB special issue on CRISPR raises many significant issues regarding the technology's potential for human (and nonhuman) germline alteration. We were surprised, however, to find little discus...
Adoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression
Authors: Sanja Stevanović, Pasetto Anna, Jared J Gartner, Eric Tran, Paul F Robbins, Steven A Rosenberg, Christian S Hinrichs
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Adoptive transfer of tumor-infiltrating lymphocytes (TIL) can mediate complete regression of metastatic cervical cancer, but the immunological landscape of the anti-tumor T cell responses in these patients is not fully understood. Reactivity against the human papillomavirus (HPV)-
Molecular cloning of CD31, a putative intercellular adhesion molecule closely related to carcinoembryonic antigen.
Authors: D L Simmons, C Walker, C Power, R Pigott
Journal: The Journal of Experimental Medicine (1990)

cDNA clones encoding CD31 have been isolated by transient expression. The sequence of CD31 expressed on human umbilical vein endothelial cells (HUVEC) is identical to that expressed on the monocyte-like cell line HL60. In HUVEC. CD31 is concentrated in regions of cell-cell contacts. CD31 is a member of the Ig superfamily and is most closely related to the carcinoembryonic antigen CEA, consisting of four contiguous C2 domains. The localization of CD31 to regions of cell-cell contacts, and the sequence similarity to CEA, a known intercellular adhesion molecule (ICAM), strongly suggest that CD31 may function as an ICAM, possibly mediating endothelial cell-cell contacts and also promoting interactions between leukocytes and endothelial cells.
Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis
Authors: John O Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M Foltz, Michael R Savona, Ron Paquette, Robert Turner, Paul Coughlin, Elliott Winton, Deborah Hunter, Albert Assad, Jason Clark, Peter O'Neill, Ronald Hoffman, Srdan Verstovsek
Journal: Blood (2014)
Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens.
Authors: N Perico, O Imberti, M Bontempelli, G Remuzzi
Journal: Journal of the American Society of Nephrology (1995)

This laboratory and others have previously shown that the intrathymic injection of donor cells or major histocompatibility complex allopeptides induced indefinite survival of a subsequent graft without immunosuppression. This approach may open interesting new perspectives for transplant medicine. Studies to explore the feasibility of the technique in humans can only be designed with some form of concomitant immunosuppression to avoid the risk of irreversible rejection in the case that the thymus approach fails. Thus, one of the first issue to address is whether conventional immunosuppression interfered with the process of thymus tolerance. This study was designed to investigate the above issue. In transplanted Lewis control rats, cyclosporin A (CsA) (10 mg/kg per day) and methylprednisolone (MP) (10 mg/kg twice daily) for 3 days were invariably followed by kidney graft rejection within 10 days. In subsequent experiments, five groups of Lewis rats were injected with medium alone or Brown-Norway (BN) leukocytes into the thymus, and 24 h later, they were orthotopically transplanted with major histocompatibility complex-incompatible kidneys from BN rats. At the time of transplantation, Lewis rats received MP (10 mg/kg twice daily) CsA (10 mg/kg per day), or the combination of the two (MP+CsA at the same dose) for 3 days. Lewis rats injected intrathymically with BN leukocytes but not receiving immunosuppressants had indefinite survival of their kidney graft. The effect of the intrathymic injection of donor cells of inducing unresponsiveness to a subsequent kidney graft was abolished by concomitant immunosuppression. All animals given immunosuppressants rejected their graft within 12 days after surgery.(ABSTRACT TRUNCATED AT 250 WORDS)
IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy
Authors: Karolina Pilipow, Alessandra Roberto, Mario Roederer, Thomas A. Waldmann, Domenico Mavilio, Enrico Lugli
Journal: Cancer Research (2015)

Preclinical models revealed that the immune system can mediate rejection of established tumors, but direct evidence in humans has been limited to largely immunogenic tumors, such as melanoma. The recent success of immune checkpoint inhibitors and adoptive T-cell transfer immunotherapy in clinical trials has instilled new hope for the use of T-cell immunotherapy in the treatment of cancer. IL15, a potent immunostimulatory cytokine, both potentiates host T-cells and natural killer (NK) cell immune responses and promotes the generation of long-lived memory T cells with superior functional capacity, with potential use in adoptive T-cell transfer protocols. IL15 has been recently tested in the clinic and showed dramatic effects at the level of responding NK and CD8(+) memory T cells. The recent advances in the knowledge of IL15-dependent regulation of T-cell responses, gene expression, and metabolic adaptation have important implications for the use of IL15 in T-cell-based immunotherapy of cancer.
Implantable Cardioverter–Defibrillator Therapy after Myocardial Infarction
Authors: Fausta Micheletta, Silvia Natoli, Luigi Iuliano
Journal: New England Journal of Medicine (2005)

to the editor: Hohnloser et al. (Dec. 9 issue), 1 who conducted the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT), assume that implantable cardioverter–defibrillator (ICD) therapy early after myocardial infarction decreases the rate of death due to arrhythmia but that the patients die of other cardiac disease. We believe alternatives must be considered. First, it should not be assumed that the mechanism of death has been changed by the ICD; rather, the presence of an ICD will affect classification (a doctor or committee member will be less likely to believe a death is due to arrhythmia if a patient has a device). It is more likely that ICD implantation has led to worsening cardiac function. Second, the implantation and testing of a defibrillator may negatively interrupt the adaptive remodeling in the dynamic postinfarction myocardium. Shocks delivered during testing of the device result in myocyte necrosis. 2 Furthermore, the effects of the implantation of the device on hemodynamic variables, including blood pressure and heart rate, predispose the myocardium to further ischemia and infarction. Neurohormonal activation and inflammation could also lead to maladaptive remodeling, hastening the downward spiral of chronic heart failure. 3 All these factors might be particularly detrimental immediately after a myocardial infarction.
In the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?
Authors: Ashraf Z Badros
Journal: Journal of the National Comprehensive Cancer Network (2010)

Multiple myeloma is characterized by clinical and biologic heterogenicity. Recently, genetic analysis has provided predictable prognosis across different types of treatment. These advances have allowed patients to be categorized into different risk groups and have been particularly useful in defining a high-risk group with short survival after standard- and high-dose chemotherapies. Preliminary studies have shown promising outcomes after the use of novel agents, such as bortezomib, thalidomide, and lenalidomide in high-risk patients, including those eligible for autologous stem cell transplantation and those who cannot or will not undergo transplantation. The application of risk-based therapy and the potential of the new agents to abrogate the influence of adverse prognostic features may improve outcomes in these patients.
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits
Authors: Sang-Won Min, Xu Chen, Tara E Tracy, Yaqiao Li, Yungui Zhou, Chao Wang, Kotaro Shirakawa, S Sakura Minami, Erwin Defensor, Sue Ann Mok, Peter Dongmin Sohn, Birgit Schilling, Xin Cong, Lisa Ellerby, Bradford W Gibson, Jeffrey Johnson, Nevan Krogan, Mehrdad Shamloo, Jason Gestwicki, Eliezer Masliah, Eric Verdin, Li Gan
Journal: Nature Medicine (2015)
Corrections: Association of variants in MMEL1 and CTLA4 with rheumatoid arthritis in the Han Chinese population (Annals of the Rheumatic Diseases (2011) 70, (1793-1797))
Authors: P. Danoy, M. Wei, H. Johanna, Matthew A. Brown, H. Xu
Journal: Annals of the Rheumatic Diseases (2011)

Patrick Danoy, Meng Wei, Hadler Johanna, et al. Association of variants in MMEL1 and CTLA4 with rheumatoid arthritis in the Han Chinese population. Ann Rheum Dis 2011;70:1793–97. The following authors were listed as contributing equally to the study...
Antiretroviral Treatment of Adult HIV Infection
Authors: Scott M. Hammer, Joseph J. Eron, Peter Reiss, Robert T. Schooley, Melanie A. Thompson, Sharon Walmsley, Pedro Cahn, Margaret A. Fischl, Jose M. Gatell, Martin S. Hirsch, Donna M. Jacobsen, Julio S. G. Montaner, Douglas D. Richman, Patrick G. Yeni, Paul A. Volberding
Journal: JAMA (2008)

<h3>Context</h3>The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral-naive and -experienced patients warrant an update of the International AIDS Society–USA guidelines for the use of antiretroviral therapy in adult human immunodeficiency virus (HIV) infection.<h3>Objectives</h3>To summarize new data in the field and to provide current recommendations for the antiretroviral management and laboratory monitoring of HIV infection. This report provides guidelines in key areas of antiretroviral management: when to initiate therapy, choice of initial regimens, patient monitoring, when to change therapy, and how best to approach treatment options, including optimal use of recently approved drugs (maraviroc, raltegravir, and etravirine) in treatment-experienced patients.<h3>Data Sources and Study Selection</h3>A 14-member panel with expertise in HIV research and clinical care was appointed. Data published or presented at selected scientific conferences since the last panel report (August 2006) through June 2008 were identified.<h3>Data Extraction and Synthesis</h3>Data that changed the previous guidelines were reviewed by the panel (according to section). Guidelines were drafted by section writing committees and were then reviewed and edited by the entire panel. Recommendations were made by panel consensus.<h3>Conclusions</h3>New data and considerations support initiating therapy before CD4 cell count declines to less than 350/μL. In patients with 350 CD4 cells/μL or more, the decision to begin therapy should be individualized based on the presence of comorbidities, risk factors for progression to AIDS and non-AIDS diseases, and patient readiness for treatment. In addition to the prior recommendation that a high plasma viral load (eg, &gt;100 000 copies/mL) and rapidly declining CD4 cell count (&gt;100/μL per year) should prompt treatment initiation, active hepatitis B or C virus coinfection, cardiovascular disease risk, and HIV-associated nephropathy increasingly prompt earlier therapy. The initial regimen must be individualized, particularly in the presence of comorbid conditions, but usually will include efavirenz or a ritonavir-boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine). Treatment failure should be identified and managed promptly, with the goal of therapy, even in heavily pretreated patients, being an HIV-1 RNA level below assay detection limits.
Outbreak of ciguatera food poisoning by consumption of amberjack (Seriola spp.) in the Canary Islands, May 2012
Authors: D Nuñez, P Matute, A Garcia, P Garcia, N Abadía
Journal: Eurosurveillance (2012)

In May 2012 a family outbreak of ciguatera food poisoning, affecting four people, was detected in Tenerife, Canary Islands. The outbreak was caused by eating amberjack fish (Seriola spp.) bought in a local market. This is the third outbreak of ciguatera food poisoning in the Canary Islands in 2012. We describe the epidemiology of this outbreak.
Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors
Authors: Linus Willerding, Simone Limmer, Martin Hossann, Anja Zengerle, Kirsten Wachholz, Timo L.M. ten Hagen, Gerben A. Koning, Ronald Sroka, Lars H. Lindner, Michael Peller
Journal: Journal of Controlled Release (2015)
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance
Authors: Laura Taddia, Domenico D’Arca, Stefania Ferrari, Chiara Marraccini, Leda Severi, Glauco Ponterini, Yahuda G. Assaraf, Gaetano Marverti, Maria Paola Costi
Journal: Drug Resistance Updates (2015)
From national to international – challenges in cross-border multi-country, multi-vehicle foodborne outbreak investigations
Authors: D Coulombier, J Takkinen
Journal: Eurosurveillance (2013)

Preview this article: From national to international – challenges in cross-border multi-country, multi-vehicle foodborne outbreak investigations, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/18/11/art20423-en-1.gif
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirintreatment in chronic hepatitis C
Authors: L.V.C. Valenti, S. De Nicola, A. Staettermayer, A.M. Aghemo, P. Maggioni, B.M. Motta, P. Ferenci, M. Colombo, S.R. Fargion
Journal: Hepatology (2011)
Premenstrual exacerbation of binge eating in bulimia
Authors: M M Gladis, B T Walsh
Journal: American Journal of Psychiatry (1987)

Several studies have suggested an association between the premenstrual phase of the menstrual cycle and changes in appetite and eating behavior. This study examined the relation between phase of menstrual cycle and frequency of binge eating in 15 normal-weight women with bulimia whose eating behavior had been unaffected by placebo treatment during a medication study. There was a modest but statistically significant premenstrual exacerbation of binge eating.
The Immunotherapy Roadmap
Authors: James C. Yang
Journal: Clinical Cancer Research (2015)

Abstract As new active agents are discovered and approved, it is clear that combinations of these immunotherapies will be needed to reject most human cancers. The era of personalized patient tumor analysis has arrived just in time to guide these combinations. Clin Cancer Res; 22(2); 275–6. ©2015 AACR. See related article by Moon et al., p. 436